Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model

Li,Dan; Qin,Qing; Wang,Xiao-Yi; Shi,Hua-Shan; Luo,Min; Guo,Fu-Chun; Wang,Wei; Wang,Yong-Sheng

doi:10.3892/or.2013.2947

Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model

Authors:
- Dan Li
- Qing Qin
- Xiao-Yi Wang
- Hua-Shan Shi
- Min Luo
- Fu-Chun Guo
- Wei Wang
- Yong-Sheng Wang
View Affiliations

Affiliations: Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R. China, Department of Endocrine Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China
Published online on: December 30, 2013 https://doi.org/10.3892/or.2013.2947
Pages: 1287-1295

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human neutrophil peptides (HNPs) 1-3 possess a high degree of similarity and are deregulated in many types of human tumors. Previous studies have demonstrated that tumor cell lines and microdissected fresh tumor cells express HNP1-3. In vitro, HNP1-3 have been reported to be cytotoxic to various types of tumor cells. Previously, we observed that the intracellular expression of HNP1 increased plasma membrane permeability in A549 cells and inhibited in vivo tumor angiogenesis. Based on these findings, we inferred that the intratumoral expression of HNP1 may benefit chemotherapy in solid tumors. In the present study, we established a mouse 4T1 breast cancer model imitating locally advanced breast cancer (LABC) and we injected the mice intratumorally with plasmid HNP1 (pHNP1). Doxorubicin (Dox) was administered twice i.v. at 5 mg/kg body weight on day 1 and 8. The possible mechanisms were investigated by evaluating cell proliferation and apoptosis, intracellular Dox accumulation, mitochondrial transmembrane potential (ΔΨm) and ultrastructural alteration of intratumoral microvessels. Compared with the single agent treatment, the combination of Dox and pHNP1 resulted in a significant delay in in vivo tumor growth and a decrease in lung metastasis. This chemosensitization effect was also observed in an A549 lung cancer model treated with cisplatin (DDP) and pHNP1. MTT assay and Annexin V staining demonstrated that 4T1 cells pre-transfected with pHNP1 were significantly more sensitive to Dox, causing increased proliferation inhibition and apoptosis. Further investigations showed that the intracellular expression of HNP1 enhanced Dox accumulation and significantly impaired mitochondrial ΔΨm. Moreover, in tumor tissues, HNP1 mediated intratumoral microvessel normalization and caused significant in situ tumor cell apoptosis. Our study suggests that intratumoral expression of HNP1 can significantly improve the therapeutic efficacy of Dox in breast cancer, abrogate the influence of multidrug resistance and enhance medication safety. Our findings may be important for the clinical therapeutic strategies of cancer chemotherapy.

View Figures

View References

1	Franceschini G, Terribile D, Magno S, et al: Update in the treatment of locally advanced breast cancer: a multidisciplinary approach. Eur Rev Med Pharmacol Sci. 11:283–289. 2007.PubMed/NCBI
2	Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005. View Article : Google Scholar : PubMed/NCBI
3	Schott AF and Hayes DF: Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 30:1747–1749. 2012. View Article : Google Scholar : PubMed/NCBI
4	Dong J, Yang G and McHaourab HS: Structural basis of energy transduction in the transport cycle of MsbA. Science. 308:1023–1028. 2005. View Article : Google Scholar : PubMed/NCBI
5	Agerberth B, Charo J, Werr J, et al: The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 96:3086–3093. 2000.
6	Obata-Onai A, Hashimoto S, Onai N, et al: Comprehensive gene expression analysis of human NK cells and CD8⁺ T lymphocytes. Int Immunol. 14:1085–1098. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ganz T, Selsted ME and Lehrer RI: Defensins. Eur J Haematol. 44:1–8. 1990. View Article : Google Scholar
8	Müller CA, Markovic-Lipkovski J, Klatt T, et al: Human α-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol. 160:1311–1324. 2002.
9	Lundy FT, Orr DF, Gallagher JR, et al: Identification and overexpression of human neutrophil α-defensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. Oral Oncol. 40:139–144. 2004.
10	Melle C, Ernst G, Schimmel B, et al: Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology. 129:66–73. 2005.
11	Holterman DA, Diaz JI, Blackmore PF, et al: Overexpression of α-defensin is associated with bladder cancer invasiveness. Urol Oncol. 24:97–108. 2006.
12	Bateman A, Singh A, Jothy S, Fraser R, Esch F and Solomon S: The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors. Peptides. 13:133–139. 1992. View Article : Google Scholar : PubMed/NCBI
13	Li J, Zhao J, Yu X, et al: Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res. 11:8312–8320. 2005. View Article : Google Scholar : PubMed/NCBI
14	Lichtenstein A, Ganz T, Selsted ME and Lehrer RI: In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood. 68:1407–1410. 1986.PubMed/NCBI
15	Barker E and Reisfeld RA: A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 53:362–367. 1993.PubMed/NCBI
16	McKeown ST, Lundy FT, Nelson J, et al: The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 42:685–690. 2006. View Article : Google Scholar : PubMed/NCBI
17	Xu N, Wang YS, Pan WB, et al: Human α-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther. 7:1588–1597. 2008.
18	Wang YS, Li D, Shi HS, et al: Intratumoral expression of mature human neutrophil peptide-1 mediates antitumor immunity in mice. Clin Cancer Res. 15:6901–6911. 2009. View Article : Google Scholar : PubMed/NCBI
19	Chavakis T, Cines DB, Rhee JS, et al: Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J. 18:1306–1308. 2004.
20	Shen G, Li Y, Du T, et al: SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy. Neoplasma. 59:486–493. 2012. View Article : Google Scholar
21	Dickson PV, Hamner JB, Sims TL, et al: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 13:3942–3950. 2007. View Article : Google Scholar
22	Bruno NA and Slate DL: Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J Natl Cancer Inst. 82:419–424. 1990. View Article : Google Scholar : PubMed/NCBI
23	Aarbiou J, Tjabringa GS, Verhoosel RM, et al: Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL-37. Inflamm Res. 55:119–127. 2006.
24	Pulaski BA, Terman DS, Khan S, Muller E and Ostrand-Rosenberg S: Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60:2710–2715. 2000.
25	Boucher Y, Baxter LT and Jain RK: Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50:4478–4484. 1990.
26	Minchinton AI and Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer. 6:583–592. 2006. View Article : Google Scholar : PubMed/NCBI
27	Jang SH, Wientjes MG, Lu D and Au JL: Drug delivery and transport to solid tumors. Pharm Res. 20:1337–1350. 2003. View Article : Google Scholar : PubMed/NCBI
28	Economopoulou M, Bdeir K, Cines DB, et al: Inhibition of pathologic retinal neovascularization by α-defensins. Blood. 106:3831–3838. 2005.
29	Zasloff M: Antimicrobial peptides of multicellular organisms. Nature. 415:389–395. 2002. View Article : Google Scholar : PubMed/NCBI
30	McPhee JB and Hancock RE: Function and therapeutic potential of host defence peptides. J Pept Sci. 11:677–687. 2005. View Article : Google Scholar : PubMed/NCBI
31	Mader JS, Salsman J, Conrad DM and Hoskin DW: Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol Cancer Ther. 4:612–624. 2005. View Article : Google Scholar : PubMed/NCBI
32	Moore AJ, Devine DA and Bibby MC: Preliminary experimental anticancer activity of cecropins. Pept Res. 7:265–269. 1994.PubMed/NCBI
33	Jacob L and Zasloff M: Potential therapeutic applications of magainins and other antimicrobial agents of animal origin. Ciba Found Symp. 186:197–216. 1994.PubMed/NCBI
34	Hui L, Leung K and Chen HM: The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. Anticancer Res. 22:2811–2816. 2002.PubMed/NCBI
35	Johnstone SA, Gelmon K, Mayer LD, Hancock RE and Bally MB: In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and P-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des. 15:151–160. 2000.
36	Lincke CR, van der Bliek AM, Schuurhuis GJ, van der Velde-Koerts T, Smit JJ and Borst P: Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res. 50:1779–1785. 1990.PubMed/NCBI
37	Ohsaki Y, Gazdar AF, Chen HC and Johnson BE: Antitumor activity of magainin analogues against human lung cancer cell lines. Cancer Res. 52:3534–3538. 1992.PubMed/NCBI
38	Fojo AT and Menefee M: Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol. 32(Suppl 7): S3–S8. 2005. View Article : Google Scholar : PubMed/NCBI
39	Doyle L and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
40	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
41	Xu RH, Pelicano H, Zhou Y, et al: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 65:613–621. 2005.
42	Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553–563. 2004.
43	Baluk P, Morikawa S, Haskell A, Mancuso M and McDonald DM: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 163:1801–1815. 2003. View Article : Google Scholar : PubMed/NCBI
44	Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK and McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 160:985–1000. 2002. View Article : Google Scholar : PubMed/NCBI
45	Adams RH and Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 8:464–478. 2007. View Article : Google Scholar : PubMed/NCBI
46	Goel S, Duda DG, Xu L, et al: Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 91:1071–1121. 2011. View Article : Google Scholar : PubMed/NCBI
47	Huang Y, Yuan J, Righi E, et al: Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 109:17561–17566. 2012. View Article : Google Scholar : PubMed/NCBI